[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

February 2017 - April 2015

Decade

Year

Issue

March 1, 2017, Vol 3, No. 3, Pages 291-423

Viewpoint

Highlights in Hematologic Malignancy TreatmentsLeukemia, Myelodysplastic Syndromes, and Allotransplant—New Drugs on the Horizon for Acute Myeloid Leukemia

Abstract Full Text
JAMA Oncol. 2017;3(3):299-300. doi:10.1001/jamaoncol.2016.3928

This Viewpoint highlights recent advances in the treatment of hematologic malignancies.

Highlights in the Treatment of Lung CancerWhat’s New? Not Much

Abstract Full Text
JAMA Oncol. 2017;3(3):301-302. doi:10.1001/jamaoncol.2016.3984

This Viewpoint highlights the studies in lung cancer treatment presented at the 2016 ASCO meeting.

Cancer Care Chronicles

From Muslim Registries to Radical Health Care Reform—Caring for Patients in an Era of Political Anxiety

Abstract Full Text
JAMA Oncol. 2017;3(3):303-304. doi:10.1001/jamaoncol.2017.0151
Editorial

Vaginal Estrogens and Aromatase InhibitorsHow Safe Is Safe Enough?

Abstract Full Text
JAMA Oncol. 2017;3(3):305-306. doi:10.1001/jamaoncol.2016.3934

Appropriate Use of Antiemetics to Prevent Chemotherapy-Induced Nausea and Vomiting

Abstract Full Text
JAMA Oncol. 2017;3(3):307-309. doi:10.1001/jamaoncol.2016.2616

Better Outcomes for Lower Costs in Breast Cancer CareFinding a Way

Abstract Full Text
JAMA Oncol. 2017;3(3):309-310. doi:10.1001/jamaoncol.2016.4544
Original Investigation

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast CancerA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2017;3(3):313-319. doi:10.1001/jamaoncol.2016.3904

This randomized clinical trial evaluates the safety of intravaginal testosterone cream vs an estradiol vaginal ring in patients with early-stage breast cancer receiving an aromatase inhibitor.

Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations

Abstract Full Text
JAMA Oncol. 2017;3(3):320-326. doi:10.1001/jamaoncol.2016.2530

This observational study provides an estimate of the baseline prevalence, trends, determinants, and costs of antiemetic overuse in patients receiving chemotherapy before and after the 2013 announcement of the Choosing Wisely guidelines.

Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care

Abstract Full Text
JAMA Oncol. 2017;3(3):327-334. doi:10.1001/jamaoncol.2016.4549

This study assesses the association of a pay-for-performance bundled-payment program vs a fee-for-service program on outcomes and medical expenditures for breast cancer in Taiwan.

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast CancerAnalysis of the NSABP B-31 Trial

Abstract Full Text
JAMA Oncol. 2017;3(3):335-341. doi:10.1001/jamaoncol.2016.4884

This secondary analysis of the NSABP B-31 trial evaluates the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab efficacy in the adjuvant treatment of ERBB2/HER2–positive breast cancer.

Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk

Abstract Full Text
JAMA Oncol. 2017;3(3):344-350. doi:10.1001/jamaoncol.2016.4096

This secondary analysis uses health insurance claims data from Japan to describe the pattern of overprescribing prophylactic antiemetic drugs to patients who have received intravenous chemotherapy.

Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer SurvivalA Case-Cohort Analysis in the Pathways Study

Abstract Full Text
JAMA Oncol. 2017;3(3):351-357. doi:10.1001/jamaoncol.2016.4188

This cohort study investigates the association of serum vitamin D levels at the time of diagnosis with breast cancer survival.

A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma

Abstract Full Text
JAMA Oncol. 2017;3(3):358-365. doi:10.1001/jamaoncol.2016.4581

This study uses National Cancer Database data and recursive partitioning analysis to compare the prognostic ability of a new proposed staging system vs 2 other staging systems for human papillomavirus–related oropharyngeal squamous cell carcinoma.

Systemic Therapy for Previously Untreated Advanced BRAF-Mutated MelanomaA Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

Abstract Full Text
JAMA Oncol. 2017;3(3):366-373. doi:10.1001/jamaoncol.2016.4877

This network meta-analysis attempts to estimate the relative efficacy and safety of systemic therapies for advanced, treatment-naive, BRAF-mutated melanoma.

Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit

Abstract Full Text
JAMA Oncol. 2017;3(3):374-381. doi:10.1001/jamaoncol.2016.4858

This longitudinal cohort study examines risk factors, mortality, length of stay, and cost associated with admission to the intensive care unit for patients with acute myeloid leukemia.

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines

Abstract Full Text
JAMA Oncol. 2017;3(3):382-390. doi:10.1001/jamaoncol.2016.4166

This analysis of health technology assessment reports examines the overall survival, quality of life, and safety benefits associated with recently licensed cancer medicines.

Second Opinions From Medical Oncologists for Early-Stage Breast CancerPrevalence, Correlates, and Consequences

Abstract Full Text
JAMA Oncol. 2017;3(3):391-397. doi:10.1001/jamaoncol.2016.5652

This study investigates the patterns and correlates of second opinion use and the effect on chemotherapy decisions.

Brief Report

Evaluation of the Feasibility of Screening Patients for Early Signs of Lung Carcinoma in Web Search Logs

Abstract Full Text
JAMA Oncol. 2017;3(3):398-401. doi:10.1001/jamaoncol.2016.4911

This log analysis of online activity of millions of web searchers evaluates the feasibility of early detection of lung carcinoma via analysis of the web searches,.

Invited Commentary

Predictive Value of FcR PolymorphismsA Further Step on the Long and Winding Road to Application

Abstract Full Text
JAMA Oncol. 2017;3(3):342-343. doi:10.1001/jamaoncol.2016.4905
Review

Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2017;3(3):402-409. doi:10.1001/jamaoncol.2016.3931

This review proposes reframing discussions around surveillance mammography in older survivors of breast cancer.

JAMA Oncology Clinical Challenge

A Rapidly Expanding Scalp Mass

Abstract Full Text
JAMA Oncol. 2017;3(3):411-412. doi:10.1001/jamaoncol.2016.5090

A woman in her 80s presented with a 2-week history of an enlarging left parietal scalp mass that continued to enlarge. She subsequently developed progressive generalized weakness, slowed speech, and focal right-handed weakness. What is your diagnosis?

Research Letter

Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference

Abstract Full Text
JAMA Oncol. 2017;3(3):414-416. doi:10.1001/jamaoncol.2016.4899

This study analyzes the quality of abstracts reporting findings of randomized clinical trials that were presented at the American Society of Clinical Oncology annual meetings in 2007 and 2015.

Comment & Response

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question

Abstract Full Text
JAMA Oncol. 2017;3(3):416. doi:10.1001/jamaoncol.2016.3941

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question—Reply

Abstract Full Text
JAMA Oncol. 2017;3(3):416-417. doi:10.1001/jamaoncol.2016.3947

Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations

Abstract Full Text
JAMA Oncol. 2017;3(3):417. doi:10.1001/jamaoncol.2016.3952

Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations—Reply

Abstract Full Text
JAMA Oncol. 2017;3(3):417-418. doi:10.1001/jamaoncol.2016.3900
Correction

Supplement 2 Added

Abstract Full Text
free access
JAMA Oncol. 2017;3(3):418. doi:10.1001/jamaoncol.2016.6886

Additional Study Contributors Reported After Publication

Abstract Full Text
free access
JAMA Oncol. 2017;3(3):418. doi:10.1001/jamaoncol.2017.0098
Poetry and Oncology

A Silver Lining

Abstract Full Text
JAMA Oncol. 2017;3(3):304. doi:10.1001/jamaoncol.2016.5993
JAMA Oncology Patient Page

Novel Precision Medicine Trial DesignsUmbrellas and Baskets

Abstract Full Text
free access
JAMA Oncol. 2017;3(3):423. doi:10.1001/jamaoncol.2016.5299
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(3):293. doi:10.1001/jamaoncol.2016.1677
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2017;3(3):291. doi:10.1001/jamaoncol.2016.1676
×